Dr. Palani Palaniappan, Aruvant's chief technology officer, will participate in a panel titled, "What's Next for Advanced Therapies," on Tuesday, October 12, from 7:15 a.m. to 8:45 a.m. PST. In addition, Dr. Will Chou, chief executive officer, will give a company presentation and provide an update on the development of ARU-1801, an investigational lentiviral gene therapy for sickle cell disease, and ARU-2801.

Aruvant will also be a corporate sponsor of the upcoming 49th Annual National Sickle Cell Disease Association of America Convention, which will be held October 12-16 and will be online.

Aruvant receives EMA orphan designation for sickle cell gene therapy
Aruvant has been granted orphan drug designation for ARU-1801, an investigational lentiviral gene therapy by the European Medicines Agency (EMA).